Influenza remains a significant public health concern, with annual vaccine formulations traditionally developed based on the most prevalent virus strains from the previous year. This process often results in mismatches between the vaccine and circulating strains, limiting efficacy. In this study, we utilize the UISS-FLU simulator to compare the effects of a novel influenza vaccine formulation, developed in our previous research, against this year's standard vaccine. We aim to evaluate the potential advantages of our formulation in terms of immunogenic response and protective efficacy. By leveraging in silico methodologies, we can enhance vaccine design and optimization, allowing for a more adaptive and responsive approach to influenza immunization. Our findings will provide insights into the future of vaccine development, showcasing how computational tools can improve public health outcomes by potentially yielding a universal vaccine solution.

The study used the Universal Immune System Simulator (UISS) to create a virtual model of cutaneous leishmaniasis (CL), a disease caused by Leishmania parasites transmitted through sandfly bites. CL can manifest in various forms, impacting millions of people globally. Current treatments face challenges, including toxicity and a lack of preventive vaccines. Researchers explored the immune response intricacies in CL, focusing on the balance between M1 and M2 macrophages, which significantly affect disease outcomes. The UISS accurately simulated the immune response, representing interactions between digital patients and Leishmania parasites. The simulation represented a scenario where the importance of M2 macrophages and Th2 cells in CL immunopathology is emphasized. These findings demonstrate UISS's potential in understanding complex host-pathogen interactions, paving the way for targeted therapies and innovative treatments in leishmaniasis.

The emergence of Variants of Concern in infectious diseases, particularly in the context of viruses like SARS-CoV-2, has highlighted the critical importance of continuous prediction and monitoring, showcasing the pivotal role of computational biology in addressing the challenges posed by these emerging infectious diseases. This study advocates for implementing a computational approach able to predict the next SARS-CoV-2 variant of concern (VOC). To that end, inspired by natural selection principles, we used the Genetic Algorithm (GA) as it offers a potent framework for optimizing complex problems. We initiated our investigation with the Wuhan spike protein sequence since it is critical target for variant surveillance and used as reference input. Subsequently, we systematically introduced specific mutations into this sequence to make the initial population. Computational modeling generated three-dimensional structures of the mutated spike within the SARS-CoV-2 ACE2 to evaluate the best candidate of each generation. These were later evaluated by predicting their Gibbs free energy (ΔG values) to evaluate the stability and interactions of these mutants, providing insights into their potential effects on viral behavior and the emergence of VOC. Our analysis demonstrates that the ΔG of our predicted variant closely compares to the delta variant, indicating a similar thermodynamic profile in their interactions. Moreover, our finding indicates that the transmission potential of the new variant is nearly on par with that of the delta variants. Additional factors will be taken into account to evaluate the overall importance of our predicted variant, and we will undertake further research and analysis to comprehend its real-world consequences and potential advantages or drawbacks.

When it was first introduced in 2000, reverse vaccinology was defined as an in silico approach that begins with the pathogen's genomic sequence. It concludes with a list of potential proteins with a possible, but not necessarily, list of peptide candidates that need to be experimentally confirmed for vaccine production. During the subsequent years, reverse vaccinology has dramatically changed: now it consists of a large number of bioinformatics tools and processes, namely subtractive proteomics, computational vaccinology, immunoinformatics, and in silico related procedures. However, the state of the art of reverse vaccinology still misses the ability to predict the efficacy of the proposed vaccine formulation. Here, we describe how to fill the gap by introducing an advanced immune system simulator that tests the efficacy of a vaccine formulation against the disease for which it has been designed. As a working example, we entirely apply this advanced reverse vaccinology approach to design and predict the efficacy of a potential vaccine formulation against influenza H5N1. Climate change and melting glaciers are critical due to reactivating frozen viruses and emerging new pandemics. H5N1 is one of the potential strains present in icy lakes that can raise a pandemic. Investigating structural antigen protein is the most profitable therapeutic pipeline to generate an effective vaccine against H5N1. In particular, we designed a multi-epitope vaccine based on predicted epitopes of hemagglutinin and neuraminidase proteins that potentially trigger B-cells, CD4, and CD8 T-cell immune responses. Antigenicity and toxicity of all predicted CTL, Helper T-lymphocytes, and B-cells epitopes were evaluated, and both antigenic and non-allergenic epitopes were selected. From the perspective of advanced reverse vaccinology, the Universal Immune System Simulator, an in silico trial computational framework, was applied to estimate vaccine efficacy using a cohort of 100 digital patients.

The COVID-19 pandemic motivated an intense debate over high transmissibility and unavailability of effective vaccine to cover all existent variants, and also has raised critical questions, such as concerns about new mutations and genetic recombination that could lead to novel variants of concerns. The density of mutation observed in the different residue indices of spike protein sequence, may correlate to the speed of virus distribution. Therefore, predicting an accurate determination of mutation rates is essential to comprehend this virus evolution and assess the risk of emergent infectious disease. The current study predicts the mutations that may be cause of new variants of concerns using a genetic algorithm approach. In this regard, we mutated randomly the wild-type sequence of SARS-CoV-2 spike protein to generate first 100 different sequences (initial population) that were modelled individually and used to evaluate their discrete optimized protein energy score. After applying cross-over and breeding 200 new generations, one of the sequences with the lowest discrete optimized protein energy score was identified and chosen for a further analysis to realize whether this sequence is potential for being the next variant of concern.

Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis, an infectious disease caused by the Leishmania parasite and transmitted by phlebotomine sandflies. CL is manifested as skin lesions, which typically evolve to ulcerative lesions and may last for months or even years, if not treated. Currently available treatments against CL involve the use of particularly toxic and overpriced drugs, which, among other things, require long times of administration and do not always lead to the complete recovery of the patient. The use of in silico technologies, as the Universal Immune System Simulator (UISS), may be helpful in finding new and potentially more effective drugs against CL.

Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system with a relapsing or progressive course, potentially leading to severe disability. In this manuscript, a well-known sensitivity analysis technique, Latin Hypercube Sampling along with Partial Rank Correlation Coefficient, was applied to an Agent-Based Model in silico trial used in Multiple Sclerosis context to evaluate the correlation of vitamin D dosage with the number of oligodendrocytes and the thymus efficiency with regulatory T cells.

Technological advances in fields such as computer modelling and simulation are playing a fundamental role, during the COVID-19 pandemic, that has been afflicting us for 2 years now. These methodologies may help in the development, assessment and monitoring for better prevention, diagnosis, treatment and generation of specific therapeutic strategies. In this perspective, in silico platforms are emerging thanks to their ability to predict the efficacy and safety of new therapies and vaccines. Here, our integrated bioinformatics pipeline for evaluating the elicited response of human immune system against every pathogen is applied to predict the cross-reactive immunity induced by pre-existing vaccinations against SARS-CoV-2 UK variants.

Abstract Background Influenza A virus is one of the leading causes of annual mortality. The emerging of novel escape variants of the influenza A virus is still a considerable challenge in the annual process of vaccine production. The evolution of vaccines ranks among the most critical successes in medicine and has eradicated numerous infectious diseases. Recently, multi-epitope vaccines, which are based on the selection of epitopes, have been increasingly investigated. Results This study utilized an immunoinformatic approach to design a recombinant multi-epitope vaccine based on a highly conserved epitope of hemagglutinin, neuraminidase, and membrane matrix proteins with fewer changes or mutate over time. The potential B cells, cytotoxic T lymphocytes (CTL), and CD4 T cell epitopes were identified. The recombinant multi-epitope vaccine was designed using specific linkers and a proper adjuvant. Moreover, some bioinformatics online servers and datasets were used to evaluate the immunogenicity and chemical properties of selected epitopes. In addition, Universal Immune System Simulator (UISS) in silico trial computational framework was run after influenza exposure and recombinant multi-epitope vaccine administration, showing a good immune response in terms of immunoglobulins of class G (IgG), T Helper 1 cells (TH1), epithelial cells (EP) and interferon gamma (IFN-g) levels. Furthermore, after a reverse translation (i.e., convertion of amino acid sequence to nucleotide one) and codon optimization phase, the optimized sequence was placed between the two EcoRV/MscI restriction sites in the PET32a+ vector. Conclusions The proposed “Recombinant multi-epitope vaccine” was predicted with unique and acceptable immunological properties. This recombinant multi-epitope vaccine can be successfully expressed in the prokaryotic system and accepted for immunogenicity studies against the influenza virus at the in silico level. The multi-epitope vaccine was then tested with the Universal Immune System Simulator (UISS) in silico trial platform. It revealed slight immune protection against the influenza virus, shedding the light that a multistep bioinformatics approach including molecular and cellular level is mandatory to avoid inappropriate vaccine efficacy predictions.